Side by side: size, value over time, results, valuation, margins, growth, debt and shareholder returns, and any of thirty figures charted over the years (up to 6).
Open these as a peer group: up to 12 companies with suggested peers, each company's rank in the group and percentile in its sector and country, saved for you or your team.
US$ billions, as reported in each year's annual results.
Revenue of the fiscal year. US dollars at each year's exchange rate.
| Measure | Cerenome, Inc.✕ CNSY · #24,705 in the world |
|---|---|
| Profile | |
| Country | 🇺🇸 USA |
| Sector | Healthcare |
| Industry | Biotechnology |
| Founded | 1996 |
| Size | |
| Market cap | $17 M |
| Revenue | $5 M |
The largest companies, each against its nearest peers in value from the same industry.
| Fiscal year | Cerenome, Inc. |
|---|---|
| 2025 | $5 MSEC |
| 2024 | $6 MSEC |
| 2023 | $5 MSEC |
| 2018 | $4 MSEC |
| 2017 | $3 MSEC |
| 2016 | $5 MSEC |
| 2015 | $5 MSEC |
| 2014 | $5 MSEC |
| 2013 | $7 MSEC |
| 2012 | $9 MSEC |
| 2011 | $8 MSEC |
| 2010 | $8 MSEC |
Sources: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports; Ed. = the company's report (editors); WD = Wikidata, citing the annual report; Cap = value.today market caps. Hover a figure for its period.
| Net income |
|---|
| $-22 M |
| Employees | 28 |
|---|
| Valuation | |
|---|---|
| Price to sales | 4.0× |
| Price to book | 4.3× |
| Free cash flow yield | -122.6% |
| Profitability | |
|---|---|
| Operating margin | -293.7% |
| Net margin | -429.8% |
| Growth | |
|---|---|
| Revenue growth | -10.5% |
| Cash | |
|---|---|
| Free cash flow margin | -400.2% |
| Altman Z-score zone | distress |
|---|
| Data as of | Market cap Oct 2026; ratios FY2025 |
|---|
Market caps from exchange data or SEC filings on the date shown (* last known value, no current one); revenue and net income from the latest annual results; ratios worked out from each company's own statements for the fiscal year shown. ▲ marks the best of these companies where higher or lower is better; size and valuation multiples are marked for no one. Definitions: methodology.